skip to content


Abzena and Telix sign licence agreement

18 July 2017 09:44

Abzena has signed a licence agreement with Telix Pharmaceuticals, a biopharmaceutical company specialising in the development and commercialisation of radiopharmaceuticals for diagnostic (imaging) and therapeutic use.

Abzena has granted Telix an exclusive worldwide, royalty bearing, sub-licensable licence to its prostate-specific membrane antigen antibodies in the field of radio-immunoconjugation.

The PSMA antibodies were created using Abzena's Composite Human Antibody technology.

Abzena said the agreement had the potential, subject to successful development, to deliver in excess of US$65 million in licence fees and milestone payments over its life, based on achievement of certain development, regulatory and commercial milestones, in addition to royalties on net sales of approved products.

Abzena and Telix have also implemented a separate services agreement to develop these products further.

At 9:44am: (LON:ABZA) Abzena Plc share price was +0.25p at 52.5p

Story provided by

Related Company: ABZA

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.